If you would like to receive the daily Market Report by email please fill out your name and email address in the sign-up form below and you will be added to our mailing list.
Tuesday,12 November 2024 at 08:16
UK & European markets opened lower, as investors assess what
U.S. President-elect Donald Trump’s return to the White House could mean for
the region’s economy amid worries about possible tariffs.
Asia-Pacific markets fellafter China’s latest stimulus measures underwhelmed and its October inflation
numbers came in lower than expected, prompting concerns over the recovery in
the world’s second-largest economy.
Gold fell to its lowest in
nearly two months, weighed down by a stronger dollar, while
investors awaited a set of key U.S. economic data and comments from Federal
Reserve officials for further clarity on the interest rate trajectory.
Oil prices eased
as investor disappointment over China's latest stimulus plan and oversupply
concerns weighed on the market, along with a stronger dollar.
In corporate news,
AstraZeneca reported a strong financial performance for the
first nine months of the year, with a 19% increase in revenue driven by solid
growth in oncology, CVRM, respiratory, and rare diseases, leading to upgraded
full-year guidance.
The FTSE 100 pharma giant said it had also submitted a new biologics licence
application for datopotamab deruxtecan in EGFR-mutated non-small cell lung
cancer, informed by phase two and three trial data, while withdrawing a prior
BLA for a broader indication.
Additionally, AstraZeneca announced positive phase three trial results for
Koselugo in adults with neurofibromatosis type 1, as well as a $3.5bn
investment to expand its research and development and manufacturing footprint
in the United States.
Markets
08:15
FTSE 100 8,080 (-0.55%)
FTSE 250 20,579 (-0.70%)
DAX 19,265 (-0.94%)
the close
Dow Jones 44,293 +0.69%
S&P 500 6,001 +0.10%
NASDAQ 19,298 +0.06%
Fixed Income
UK 10-YR YIELD 4.455
Exchange Rates
GBP/USD 1.280
GBP/EUR 1.204
Commodities
Gold $2,603 (-0.59%)
Brent $71.89 +0.20%
Important - No news or research item should be construed as a recommendation to trade. The inclusion of securities within this report does not necessarily imply their suitability for individual portfolios or situations in respect of which further advice should be sought. Information contained in this report has been compiled from sources believed to be reliable but is not warranted to be accurate or complete.
We use cookies to improve your experience on our website. By continuing to browse, you agree to our use of cookies. Cookie Policy